1. Home
  2. PGY vs NNNN Comparison

PGY vs NNNN Comparison

Compare PGY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGY
  • NNNN
  • Stock Information
  • Founded
  • PGY 2016
  • NNNN 2021
  • Country
  • PGY United States
  • NNNN Germany
  • Employees
  • PGY N/A
  • NNNN N/A
  • Industry
  • PGY Finance: Consumer Services
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • PGY Finance
  • NNNN Health Care
  • Exchange
  • PGY Nasdaq
  • NNNN Nasdaq
  • Market Cap
  • PGY 2.6B
  • NNNN 2.2B
  • IPO Year
  • PGY N/A
  • NNNN 2025
  • Fundamental
  • Price
  • PGY $37.26
  • NNNN $47.85
  • Analyst Decision
  • PGY Strong Buy
  • NNNN
  • Analyst Count
  • PGY 8
  • NNNN 0
  • Target Price
  • PGY $37.13
  • NNNN N/A
  • AVG Volume (30 Days)
  • PGY 3.9M
  • NNNN 75.7K
  • Earning Date
  • PGY 08-07-2025
  • NNNN 01-01-0001
  • Dividend Yield
  • PGY N/A
  • NNNN N/A
  • EPS Growth
  • PGY N/A
  • NNNN N/A
  • EPS
  • PGY N/A
  • NNNN 0.06
  • Revenue
  • PGY $1,153,015,000.00
  • NNNN $8,185,146.00
  • Revenue This Year
  • PGY $27.97
  • NNNN N/A
  • Revenue Next Year
  • PGY $16.50
  • NNNN N/A
  • P/E Ratio
  • PGY N/A
  • NNNN $878.62
  • Revenue Growth
  • PGY 24.59
  • NNNN 21.95
  • 52 Week Low
  • PGY $8.20
  • NNNN $5.18
  • 52 Week High
  • PGY $41.48
  • NNNN $55.65
  • Technical
  • Relative Strength Index (RSI)
  • PGY 63.91
  • NNNN N/A
  • Support Level
  • PGY $34.76
  • NNNN N/A
  • Resistance Level
  • PGY $38.86
  • NNNN N/A
  • Average True Range (ATR)
  • PGY 2.56
  • NNNN 0.00
  • MACD
  • PGY 0.14
  • NNNN 0.00
  • Stochastic Oscillator
  • PGY 78.86
  • NNNN 0.00

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: